- $489.89m
- $292.07m
- $0.43m
Annual balance sheet for Altimmune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 37.2 | 216 | 190 | 185 | 198 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.65 | 12.4 | 5.84 | 2.54 | 4.85 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 39.4 | 230 | 204 | 193 | 210 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.8 | 1.96 | 2.25 | 1.68 | 1.01 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 54.1 | 245 | 219 | 207 | 211 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.92 | 12 | 18.3 | 17.1 | 12.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.54 | 19.2 | 19.7 | 21.6 | 16.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 45.5 | 226 | 199 | 185 | 194 |
| Total Liabilities & Shareholders' Equity | 54.1 | 245 | 219 | 207 | 211 |
| Total Common Shares Outstanding |